ALGS Q3 2024 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-60.8% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$20M-1586.4% margin

Net Income

-$19M-1517.7% margin

EPS (Diluted)

$-3.07

QoQ Revenue Growth

+19.6%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$88M

Total Liabilities

$38M

Stockholders' Equity

$50M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$3M	-60.8%
Gross Profit	$1M	$3M	-60.8%
Operating Income	-$20M	-$19M	-5.6%
Net Income	-$19M	-$18M	-6.8%